Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Cash from Financing Activities (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Cash from Financing Activities for 8 consecutive years, with -$11.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities changed 0.01% year-over-year to -$11.3 million, compared with a TTM value of -$45.2 million through Dec 2025, down 33.54%, and an annual FY2025 reading of -$45.2 million, down 33.54% over the prior year.
  • Cash from Financing Activities was -$11.3 million for Q4 2025 at Puma Biotechnology, roughly flat from -$11.3 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $9.8 million in Q1 2022 and bottomed at -$31.9 million in Q3 2021.
  • Average Cash from Financing Activities over 4 years is -$8.2 million, with a median of -$11.3 million recorded in 2024.
  • The sharpest move saw Cash from Financing Activities crashed 74353.49% in 2021, then surged 121650.0% in 2022.
  • Year by year, Cash from Financing Activities stood at -$2000.0 in 2021, then soared by 121650.0% to $2.4 million in 2022, then crashed by 566.1% to -$11.3 million in 2024, then decreased by 0.01% to -$11.3 million in 2025.
  • Business Quant data shows Cash from Financing Activities for PBYI at -$11.3 million in Q4 2025, -$11.3 million in Q3 2025, and -$11.2 million in Q2 2025.